Close Menu

NEW YORK (GenomeWeb) – ArcherDx announced today that it has raised $60 million in a Series B financing round.

ArcherDx said it will use the proceeds from the funding round to scale operations and advance its companion diagnostic program, which includes solid tumors, hematological malignancies, and circulating tumor DNA applications. The firm will also use the funding to further expand its minimal residual disease (MRD) monitoring program.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.